Unstable angina · patients with acute coronary syndrome
Statins probably leads to lower unstable angina compared with control at 4 months (3 to 6 months) (moderate certainty).
1 finding from 1 review
Acute Heart Failure · patients with acute coronary syndrome
Statins showed no clear difference in acute heart failure compared with control at 4 months (3 to 6 months) (moderate certainty).
1 finding from 1 review
Rhabdomyolysis · patients with acute coronary syndrome
Statins showed no clear difference in rhabdomyolysis compared with control at 4 months (3 to 6 months) (low certainty).
1 finding from 1 review
Change in ADAS‐Cog
1 finding from 1 review
Change in MMSE
1 finding from 1 review
Change in CGIC
1 finding from 1 review
Change in NPI
1 finding from 1 review
Early all‐cause mortality (≤ 3 months) Reported at: 28 days; 60 days; and during hospital stay · adults with acute respiratory distress syndrome
Statins showed no clear difference in early all‐cause mortality (≤ 3 months) Reported at: 60 days; and… compared with control (moderate certainty).
1 finding from 1 review
Late all‐cause mortality ( > 3 months · adults with acute respiratory distress syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of mechanical ventilation · adults with acute respiratory distress syndrome
1 finding from 1 review
Ventilator‐free days up to day 28 · adults with acute respiratory distress syndrome
1 finding from 1 review
Discontinuation of medication due to adverse events · adults with acute respiratory distress syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fitness to return to work at 12 months · adults with acute respiratory distress syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relapse · Multiple sclerosis
It is very uncertain whether statins plus beta interferon changes number of participants with relapses at 12 months Number of… compared with beta interferon (very low certainty).
2 findings from 1 review
Number of participants with progression at 12 months3 ‐ not reported · Multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants with progression at 24 months Number of participants with progression at 24 months · Multiple sclerosis
It is very uncertain whether statins plus beta interferon changes number of participants with progression at 24 months Number of… compared with beta interferon (very low certainty).
1 finding from 1 review
Number of participants with new T2 or GELs at 12 months Number of participants with new T2 or GELs at 12 months · Multiple sclerosis
It is very uncertain whether statins plus beta interferon changes number of participants with new T2 or GELs at 12 months Number of… compared with beta interferon (very low certainty).
1 finding from 1 review
Number of participants with new T2 or GELs at 24 months3 ‐ not reported · Multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Change in disability Assessed by: EDSS · Multiple sclerosis
1 finding from 1 review
Overall survival · children and adults with Smith‐Lemli‐Opitz syndrome
The review found no eligible studies for this question.
1 finding from 1 review